About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting

  • Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120th AUA Annual Meeting on Sunday, April 27, 2025.
  • Study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up.

AUSTIN, Texas, April 29, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced the positive final results of the Focal Ablation Versus Radical Prostatectomy (FARP) Study, the first randomized controlled trial completed comparing ultrasound energy-based focal ablation versus Robotic Prostatectomy. The study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up.

“The purpose of this study was to generate scientific Level 1 evidence comparing focal therapy for the treatment of clinically-significant localized prostate cancer versus robotic prostatectomy,” said Eduard Baco, MD, PhD, Associate Professor at the Department of Cancer Surgery at the Oslo University Hospital and Principal Investigator of the FARP Study. “Our final 3-year results met the primary endpoint of showing non-inferiority between the two arms of the trial, with the results showing a significantly lower rate of treatment failure in the focal ablation arm compared to the robotic prostatectomy arm. The findings from this randomized controlled trial provide significant additional evidence that support the use of focal ablation with ultrasound energy for the management of organ-localized prostate cancer, in particular HIFU.”

FARP Trial Results

  • A total of 213 patients were enrolled in the study; 107 were randomized to FA and 106 to RP.
  • 25% (26/106) of the patients in the RP arm refused surgery and crossed-over to the FA arm.
  • The two arms were equivalent in terms of mean age (64 vs. 66 years, p=0.3), PSA (8.6 vs. 8.5 ng/ml, p=0.9), index tumor diameter on MRI (14.5 vs. 15.5 mm, p=0.2), prostate volume (41.3 vs. 41.7 ml, p=0.9) and Gleason Grade Group on biopsy.
  • All included patients were evaluated following an intention-to-treat (ITT) analysis.
  • The proportion of treatment failure was 5.6% in the FA arm (6/107; 95% CI [3 – 13]) vs 7.9% in the RP arm (8/101, 95% CI [5 - 15]), resulting in a statistical difference of 2.3% (95% CI [-4.9 – 9.9]) in favor of Focal Ablation.

“The positive results from the FARP randomized controlled trial further validate the role of robotic focal ablation with ultrasound energy in the management of prostate cancer,” said Ryan Rhodes, Chief Executive Officer of EDAP TMS. “Focal One Robotic HIFU was used for the vast majority of the patients treated with focal ablation in this study. This demonstrates Focal One’s leadership position in the rapidly growing treatment category of focal therapy for prostate cancer. We anticipate that the positive data from the FARP trial, once published, combined with the recent publication of the HIFI Study, the largest prospective, comparative study ever conducted demonstrating Focal One’s ability to provide comparable cancer control and superior urinary and erectile function preservation as compared to surgery, will be instrumental in further accelerating adoption of Focal One Robotic HIFU.”

A link to the FARP Study abstract can be found here.

About EDAP TMS SA

A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP TMS introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.

Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.